Compare VERO & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERO | XRTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | VERO | XRTX |
|---|---|---|
| Price | $1.87 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.1K | ★ 50.0K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $0.52 |
| 52 Week High | $14.50 | $1.79 |
| Indicator | VERO | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 46.51 |
| Support Level | $1.84 | $0.61 |
| Resistance Level | $1.99 | $0.67 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.78 | 50.45 |
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.